

2nd International Symposium

Integrated Biomarkers in Cardiovascular Disease

Berlin (Germany) June 21-23, 2007

Hilton Berlin Hotel

Under the auspices of: International Atherosclerosis Society - German Cardiac Society - German HeartFailure Network

COMMITTEES

Chairpersons: R Dietz (D), V Fuster (USA), R Paoletti (I)

Director: SM Marcovina (USA)

Scientific Board (Preliminary list): ZA Fayad (USA), JC Kaski (UK), W Koenig (D), J Sobesky (D), E Tremoli (I), SA Williams (USA)

Scientific-Organizing Committee: E Folco (Milan, Italy, Houston, TX, USA), M Möckel (Berlin, Germany), AP Peracino (Milan, Italy), J Schulz-Menger (Berlin, Germany)

International Advisory Board: JJ Albers (USA), NL Anderson (USA), G Assmann (D), P Bonini (I), BG Brown (USA), WV Brown (USA), G Calvo (SP), AL Catapano (I), A Chait (USA), F Crea (I), G Dagher (F), J Davignon (CND), U de Faire (SW), M Denaro (I), JC Fruchart (F), M Galvani (I), H Greten (D), SM Grundy (USA), B Hamm (D), D Hochstrasser (CH), A Jacobs (D), AS Jaffe (USA), B Jönsson (SW), U Landmesser (D), P Libby (USA), TA Metcalfe (CH), TA Miettinen (FNL), C Mittmann (D), P Mocarelli (I), SE Nissen (USA), DG Orloff (USA), M Panteghini (I), M Pepi (I), PL Pieri (I), M Plebani (I), P Ridker (USA), N Rifai (USA), L Shaw (USA), EJ Schaefer (USA), G Siest (F), SC Smith, Jr (USA), A Sniderman (CND), H Sucka (D), JC Tardif (CND), A von Eckardstein (CH), G Walldius (SW)

SCOPE OF THE SYMPOSIUM

In the past few years the use of biomarkers in clinical settings has been the focus of intense scientific interest. This Symposium is aimed at taking a step forward by discussing the integration between biochemical and bioimaging markers.

The rapid development of *Biomarkers* requires:

- Strict cooperation of scientists from industry, academia, and national and international agencies to improve and accelerate the development of *Integrated Biomarkers* in human pathophysiology and drug design;
- The increase of the predictive value of *Integrated Biomarkers* to support their use and to reduce the uncertainty in the acceptance of biomarkers as a tool;
- Consolidated criteria for the definition, acceptance, or rejection of *Integrated Biomarkers* to meet the needs of different stakeholders and to integrate the different expertises to support clinical decision-making as well as drug development and assessment.

MAIN TOPICS

- The use of *Integrated Biomarkers* in the clinical setting and in clinical trials for drug development;
- Criteria and requirements for validation and use of integrated bioimaging and biochemical markers;
- Methodological assessment of *Integrated Biomarkers* in clinical evaluation, bioinformatics, proteomics, molecular imaging, regulatory requirements, and health economics;
- Models of validation of *Integrated Biomarkers* in diagnosis, prevention, therapy, and drug development in cardiocerebrovascular diseases;
- The use of *Integrated Biomarkers* in primary prevention.

SCIENTIFIC PROGRAM

The Scientific Program will include:

Plenary sessions:

- Introduction on the use of integrated bioimaging and biochemical markers
- Clinical cases: practical demonstrations
- The road to the integrated approach in primary and secondary prevention, and in treatment monitoring
- The road to the integrated approach in clinical trials and drug development
- Integrated approach and surrogate endpoints
- Integrated approach: next steps
- The stakeholders' points of view on the validation of integrated biomarkers

Clinical cases: practical demonstrations: An exciting addition to the program of the 2nd International Symposium will be the discussion of clinical cases where the integration of biomarkers is used. Thanks to the collaboration with the Charité Hospital of Berlin, key cases will be recorded and presented during the Symposium. The selected cases will focus on: ACS, Pulmonary Embolism, Inflammatory Disease of the Heart, and Stroke. The experts from the Charité Hospital will present their procedures and the benefits resulting from integrated approaches.

Round Table "The stakeholders' points of view on the validation of integrated biomarkers": Scientists and representatives from regulatory agencies, health organizations, scientific societies, and industry will present their views on the use of integrated biomarkers in cardiovascular diseases as well as their needs to comply with regulatory and evidence based medicine issues in the development of clinical trials.

Poster Sessions for submitted papers will also be organized.

A **Scientific Exhibit** will be held in the Exhibition Area during the Symposium.

SCIENTIFIC-ORGANIZING SECRETARIATS

Main Office - Biomarkers 2007

Fondazione Giovanni Lorenzini

Medical Science Foundation

Via Appiani, 7 - 20121 Milan, Italy

Phone: +39-02-29006267 - Fax: +39-02-29007018

Email: biomarkers@lorenzinifoundation.org

Branch Office - Biomarkers 2007

Giovanni Lorenzini Medical Foundation

6535 Fannin, MS A-601- Houston,

Texas 7030-2704 USA

Phone: +1-713-797-0401 - Fax: +1-713-796-8853

E-mail: biomarkers@bcm.tmc.edu